Leqembi use in South Korean Alzheimer's patients
Part of Brain & nervous system, Mental health clinical trials.
This study follows people with Alzheimer's who are already taking Leqembi (lecanemab) after being in the JOY-ALZ study. It collects medical information to check how the treatment works in real-world use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are already part of the JOY-ALZ study.
- Your doctor has already decided to start you on Leqembi (lecanemab).
- You agree to let your medical information be shared with the study sponsor.
- You are not taking part in any other research study that tests a new treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment (X/T plus X-EC) for people with Alzheimer's who are already taking Leqembi (lecanemab). It aims to see if the new drug is safe and well-tolerated.
This study collects real-world safety information from people taking the Alzheimer's drug LEQEMBI (also known as lecanemab). It helps doctors understand how well the medicine works outside of clinical trials and what side effects may occur.
This study collects information from people in Canada who have Alzheimer's disease and are prescribed the drug lecanemab (LEQEMBI). It helps doctors learn more about the drug's safety and effects in real-world use.
This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.